The effects of the competitive NMDA receptor antagonist CPP on the high pressure neurological syndrome in a primate model.
Neurophysiological interactions between the competitive N-methyl-D-aspartate (NMDA) preferring receptor antagonist, CPP (3-((+-)-2-carboxypiperazine-4-yl)-propyl-1-phosphonate) and the high pressure neurological syndrome (HPNS) have been investigated in the non-human primate Papio anubis. Eight animals were exposed on two occasions to environmental pressures of 81 atmospheres absolute (ATA) in a hyperbaric chamber, using helium and oxygen. One exposure followed pretreatment with CPP (either 5 or 10 mg/kg i.v. plus 5 mg/kg/hr infusion), the other a saline control. Pretreatment with CPP delayed moderate signs of face tremor and myoclonus and abolished severe signs of whole body tremor and seizure activity. By 81 ATA, scores representing severity of HPNS were significantly reduced by CPP to a mean score, reflecting a level of just mild to moderate limb tremoring (P less than 0.001). Changes in the EEG were observed in channels associated with the frontal, parietal and occipital regions of the left cortex. Amplitude and frequency spectra were calculated and changes with pressure in the 4 conventional wavebands were analysed. The most striking change was the complete prevention by CPP of the 100% increase in the amplitude of alpha waves at 81 ATA in the frontal region (P less than 0.001). It is concluded that NMDA transmission has a major role in the expression of HPNS.
Pearce
P C
PC
HPNS Research Group, Division of Anaesthesia, Clinical Research Centre, Harrow, Middlesex, U.K.
Halsey
M J
MJ
MacLean
C J
CJ
Ward
E M
EM
Webster
M T
MT
Luff
N P
NP
Pearson
J
J
Charlett
A
A
Meldrum
B S
BS
D000818:Animals; D000927:Anticonvulsants / Q000097:blood / Q000494:pharmacology*; D001274:Atmospheric Pressure; D001522:Behavior, Animal / Q000187:drug effects; D004569:Electroencephalography; D005260:Female; D006610:High Pressure Neurological Syndrome / Q000378:metabolism / Q000503:physiopathology*; D008954:Models, Biological; D010215:Papio; D010879:Piperazines / Q000097:blood / Q000494:pharmacology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*
D000927:Anticonvulsants; D010879:Piperazines; D016194:Receptors, N-Methyl-D-Aspartate; C050592:3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid